A Long Term Safety Study of BCX7353 in Hereditary Angioedema
Study sponsor: BioCryst Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-04-27Actual
Enrollment · participants387Actual
Source updated2023-06-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.